ALK and non-small cell lung carcinoma: Without access to individual claims and medical records, we could not determine the exact number of patients with EGFR- and ALK-altered metastatic NSCLC, nor could we determine the number of patients who filled prescriptions for osimertinib and alectinib, as opposed to the aggregate use of these drugs.